Evidence map›Paper›PMID 40133298›Full record

ArticleScientific reports2025

Comparative metagenomic analysis of the oral microbiome in COVID-19 patients and healthy individuals.

Piyush Bhanu, Sakshi Buchke, Nisha Hemandhar-Kumar, Piyush Varsha, S K Ravi Kiran, G Vikneswaran, Arjun Alva, G S Basavaraj, Jitendra Kumar

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Oral and plasma microbiome in the context of acute febrile illness.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Piyush Bhanu *Xome Life Sciences Pvt. Ltd., Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City, Bangalore, India. pb.inresearch@gmail.com.
Sakshi Buchke *Xome Life Sciences Pvt. Ltd., Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City, Bangalore, India.
Nisha Hemandhar-KumarXome Life Sciences Pvt. Ltd., Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City, Bangalore, India.
Piyush VarshaXome Life Sciences Pvt. Ltd., Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City, Bangalore, India.
S K Ravi KiranNarayana Hrudayalaya Hospital, Narayana Hrudayalaya Ltd., Bommasandra Industrial Area, Hosur Road, Anekal Taluk, Bangalore, Karnataka, India.
G VikneswaranNarayana Hrudayalaya Hospital, Narayana Hrudayalaya Ltd., Bommasandra Industrial Area, Hosur Road, Anekal Taluk, Bangalore, Karnataka, India.
Arjun AlvaNarayana Hrudayalaya Hospital, Narayana Hrudayalaya Ltd., Bommasandra Industrial Area, Hosur Road, Anekal Taluk, Bangalore, Karnataka, India.
G S BasavarajNarayana Hrudayalaya Hospital, Narayana Hrudayalaya Ltd., Bommasandra Industrial Area, Hosur Road, Anekal Taluk, Bangalore, Karnataka, India.
Jitendra KumarBiotechnology Industry Research Assistance Council (BIRAC), H728+H5G, NSIC Estate, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi, India. md.birac@nic.in.

Funding

Bangalore Bioinnovation Centre 20210001
6 · The paper itself

Abstract

COVID-19, caused by SARS-CoV-2, affects multiple body systems, including the oral cavity, where it may disrupt the oral microbiome in ways that contribute to disease pathology. Understanding the long-term interaction between SARS-CoV-2 and the oral microbiome is crucial, as it may reveal microbial markers valuable for diagnosing or monitoring persistent health issues in COVID-19 survivors. Metagenomic sequencing revealed significant microbial shifts in the oral microbiome of COVID-19 patients, showing reduced microbial diversity and increased prevalence of opportunistic pathogens compared to healthy individuals. Alpha diversity measures indicated lower microbial diversity and evenness, while beta diversity analyses demonstrated distinct microbial community compositions. Core microbiome analysis identified unique taxa in COVID-19 patients that may contribute to disease pathology, while differential abundance analysis highlighted specific taxa shifts, including an increase in potential pathogens. Our findings advance the understanding of microbial changes in the oral microbiome associated with COVID-19 and suggest potential targets for microbiome-based interventions. While these results indicate associations with possible health impacts, further research is needed to determine causative links and long-term implications for COVID-19 survivors. This foundational research highlights the potential for microbiome science to inform diagnostic tools, such as microbial markers for disease progression, and therapeutic approaches, including targeted probiotics, which could ultimately support better patient outcomes and public health strategies.

Indexed as

COVID-19MetagenomicsMicrobiotaMouthAdultCase-Control StudiesFemaleHumansMaleMiddle AgedSARS-CoV-2COVID-19Long-term healthMetagenomic sequencingMicrobial diversityMicrobial dysbiosisMicrobiome-modulating therapiesOral microbiomePathogenicityProbioticsPublic health strategiesSARS-CoV-2Therapeutic interventions

Identifiers

PMID40133298
PMCPMC11937335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.